The Toxicity of Deglycosylated Ricin A Chain-containing Immunotoxins in Patients with Non-Hodgkin's Lymphoma is Exacerbated by Prior Radiotherapy: a Retrospective Analysis of Patients in Five Clinical Trials
Overview
Affiliations
A retrospective analysis of 102 patients with relapsed, non-Hodgkin's lymphoma treated with two different ricin A chain-containing immunotoxins (ITs) in five Phase I clinical trials indicates that the dose-limiting toxicity, vascular leak syndrome, was more frequent and more severe in patients who had undergone prior radiotherapy (RT). Excluding patients with prior RT from the calculations of the maximum tolerated dose indicates that the maximum tolerated doses of these ITs had not been reached in any trial and are clearly higher than reported previously. Excluding patients with prior RT from future clinical trials may increase the dose of ITs that can be given in the absence of severe vascular leak syndrome.
Groth C, van Groningen L, Matos T, Bremmers M, Preijers F, Dolstra H Biol Blood Marrow Transplant. 2018; 25(4):712-719.
PMID: 30399420 PMC: 6595479. DOI: 10.1016/j.bbmt.2018.10.020.
Clinical targeting recombinant immunotoxins for cancer therapy.
Li M, Liu Z, Liu X, Hui Q, Lu S, Qu L Onco Targets Ther. 2017; 10:3645-3665.
PMID: 28790855 PMC: 5530862. DOI: 10.2147/OTT.S134584.
Tome-Amat J, Olombrada M, Ruiz-de-la-Herran J, Perez-Gomez E, Andradas C, Sanchez C Springerplus. 2015; 4:168.
PMID: 25883890 PMC: 4393403. DOI: 10.1186/s40064-015-0943-5.
Advances in anticancer immunotoxin therapy.
Alewine C, Hassan R, Pastan I Oncologist. 2015; 20(2):176-85.
PMID: 25561510 PMC: 4319635. DOI: 10.1634/theoncologist.2014-0358.
DAvino C, Paciello R, Riccio G, Coppola C, Coppola M, Laccetti P Protein Eng Des Sel. 2014; 27(3):83-8.
PMID: 24421342 PMC: 3925340. DOI: 10.1093/protein/gzt065.